Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22485142 | 0.79 | CHRNA7 (0.33) | SMN1; SMN2CHRNA7MAPK1L3MBTL1CYP2D6 | |
| Propane SCHEMBL28340961 | 0.76 | MEN1 (0.31) | MAPK1L3MBTL1KMT2A | |
| SCHEMBL21428541 | 0.74 | MAPK1 (0.31) | SMN1; SMN2CHRNA7MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL24784481 | 0.73 | — | — | |
| SCHEMBL27522076 | 0.73 | — | — | |
| SCHEMBL577052 | 0.71 | CHRNA7 (0.48) | SMN1; SMN2HSD11B1CHRNA7CYP2D6ALDH1A1 | |
| SCHEMBL577415 | 0.71 | CHRNA7 (0.48) | SMN1; SMN2HSD11B1CHRNA7CYP2D6ALDH1A1 | |
| SCHEMBL84808 | 0.71 | CHRNA7 (0.48) | SMN1; SMN2HSD11B1CHRNA7CYP2D6ALDH1A1 | |
| SCHEMBL262312 | 0.71 | — | — | |
| SCHEMBL6657817 | 0.71 | CHRNA7 (0.48) | SMN1; SMN2HSD11B1CHRNA7CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308163-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | SMN1; SMN2 318/4885HSD11B1 4791/4885CHRNA7 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.